MONICA-SC: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With Immune Thrombocytopenic Purpura (ITP)

Trial Profile

MONICA-SC: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With Immune Thrombocytopenic Purpura (ITP)

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2015

At a glance

  • Drugs Blisibimod (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Therapeutic Use
  • Acronyms MONICA-SC
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 29 Jul 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 05 Aug 2014 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, according to the ClinicalTrials.gov record.
    • 05 Aug 2014 Planned initiation date changed from 1 Dec 2014 to 1 Dec 2015, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top